Inorganic Chemistry, Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 1, 2024
In this work, we describe the complex formation and radiochemistry of cyclen-based chelator DOTI-Me bearing four methylimidazole arms. Radiolabeling properties were evaluated for
Language: Английский
Cancers, Journal Year: 2024, Volume and Issue: 16(11), P. 1974 - 1974
Published: May 23, 2024
The objective of this retrospective study is to assess the effectiveness and safety two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [177Lu]Lu [161Tb]Tb, in heavily treated patients with metastatic castration-resistant prostate cancer (mCRPC). A total 148 cycles PSMA radioligand therapy were given 53 at a specialized care center Amman, Jordan. This treatment was offered following exhaustion all prior modalities. Approximately half cases (n = 26) demonstrated an initial partial response therapy. Moreover, roughly one-fourth 13) exhibited sustained satisfactory biochemical response, which qualified them receive six maintain continued follow-up for additional cycles. reflected by adequate (PSA) decline concomitant evident on [68Ga]Ga-PSMA positron emission tomography/computed tomography imaging. minority (n= 18; 34%) experienced side effects. Generally, these low-grade self-limiting toxicities. endorses previous research evidence about therapy's efficacy. It also provides first clinical insight from Arab ethnicity. should facilitate promote further evidence, both regionally internationally.
Language: Английский
Citations
6
Journal of Nuclear Medicine, Journal Year: 2024, Volume and Issue: 65(5), P. 686 - 687
Published: April 11, 2024
Radiopharmaceutical therapy (RPT) is now widely recognized as an effective modality transforming cancer management. Within the last decade, prospective clinical trials using 177Lu-labeled therapies have led to widespread adoption of [177Lu]Lu-DOTA-octreotate for patients with
Language: Английский
Citations
4
Materials, Journal Year: 2025, Volume and Issue: 18(2), P. 248 - 248
Published: Jan. 8, 2025
Due to their intriguing emission profile, Terbium-161 (161Tb) radiopharmaceuticals seem bring significant advancement in theranostic applications cancer treatment. The combination of 161Tb with nanoscale brachytherapy as an approach for treatment is particularly advantageous and promising. Herein, we propose the application a hybrid nanosystem comprising gold decorated (Au@TADOTAGA) iron oxide nanoflowers form injectable nanobrachytherapy local breast cancer. More specifically, Au@TADOTAGA NFAu@TADOTAGA NPs were efficiently radiolabeled 161Tb, vitro stability was assessed up 21 d post-radiolabeling. Furthermore, cytotoxic profile against 4T1 cells evaluated, ex vivo biodistribution characteristics revealed after intratumoral injection same animal model. enhanced retention at tumor site urged us evaluate therapeutic effect [161Tb]Tb-NFAu@TADOTAGA administration 4T1-tumor-bearing mice, over period 24 days. Three different protocols performed order identify which would offer optimum results proposed promising agent.
Language: Английский
Citations
0
BMC Medical Imaging, Journal Year: 2025, Volume and Issue: 25(1)
Published: Jan. 28, 2025
Quantitative molecular imaging via single-photon emission computed tomography-derived standardised uptake value (SPECT/CT-SUV) is used to assess the response of metastatic castration-resistant prostate cancer (mCRPC) patients targeted radionuclide therapy (TRT) with [177Lu]Lu-PSMA. This technique determines radiopharmaceutical distribution and internal dosimetry in who receive TRT. However, there limited evidence regarding role image quantification monitoring changes induced by systematic examines quantitative SPECT/CT-SUV during [177Lu]Lu-PSMA TRT assesses whether SUV correlate biomarkers. A review was conducted accordance PRISMA guidelines. The MEDLINE/PubMed databases were searched from January 2016 July 2024 identify relevant articles. inclusion criterion use for mCRPC. records screened determine their eligibility. abstracts 62 screened, 28 excluded because they not relevant; full texts 34 original papers retrieved assessed total five studies included this (two prospective three retrospective studies). sample sizes ranged 6 73 patients. highest number lesions analysed 144. Three reported following cycle 1, only one study correlation pretherapy PET/CT (r = 0.9, p 0.005). between first two cycles study. None normal organs. One correlations SPECT/CT-derived PET/CT-derived target nontarget tissues. can be predict responses subsequent PSMA-TRT cycles. Disease burden tumour heterogeneity are leading causes individualisation.
Language: Английский
Citations
0
European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0
Nuclear Medicine and Biology, Journal Year: 2025, Volume and Issue: 144-145, P. 108998 - 108998
Published: Feb. 12, 2025
Language: Английский
Citations
0
Journal of Biosciences and Medicines, Journal Year: 2025, Volume and Issue: 13(02), P. 169 - 189
Published: Jan. 1, 2025
Language: Английский
Citations
0
Radiochimica Acta, Journal Year: 2025, Volume and Issue: unknown
Published: April 21, 2025
Abstract Terbium-161 ( 161 Tb) is emerging as a promising radionuclide for cancer therapy due to its favorable nuclear properties that are similar clinically established lutetium-177 177 Lu) along with therapeutic edge arising from the higher number of Auger and conversion electrons per decay. These low energy result in cytotoxicity within short range decaying nuclei enhance efficacy. Despite these characteristics, significant challenge remains lack domestic Tb supply United States, which poses an obstacle advancement Tb-based radiopharmaceutical research development. This study developed reliable cation-exchange high-performance liquid chromatography-based method purification reactor-produced at quantities suitable support preclinical studies. The purified product showed high radionuclidic purity excellent radiochemical purity, successful labeling studies DOTA chelator DOTA-TATE peptide demonstrated effective incorporation into radiopharmaceuticals designed targeted therapy.
Language: Английский
Citations
0
Clinical Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: May 16, 2025
This report explores the application of terbium-161 [( 161 Tb)Tb] DOTATATE in case a 31-year-old man with recurrent paraganglioma. Due to liver metastases and inoperable nodal disease, he was treated lutetium-177 177 Lu)Lu] DOTATATE, resulting decreased chromogranin A levels stable disease. Logistical challenges acquisition resulted treatment [ Tb]Tb-DOTATATE, demonstrating prominent lesion uptake, further reduction levels, no adverse effects. He maintains an excellent functional status 19 months progression-free survival after 3 total cycles Lu]Lu suggesting Tb]Tb-DOTATATE as promising alternative radionuclide therapy for advanced neuroendocrine tumors.
Language: Английский
Citations
0
European Urology Focus, Journal Year: 2024, Volume and Issue: 10(4), P. 514 - 517
Published: July 1, 2024
Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become readily available therapeutic option since the approval of [
Language: Английский
Citations
3